Global CD19 Therapeutics Market, 2016 - 2030 - The Promising Pipeline of Anti-CD19 Drugs Is Expected to Result in a Multi-Billion Dollar Market

Dublin, April 15, 2016 -- Research and Markets has announced the addition of the "CD19 Therapeutics Market, 2016 - 2030" report to their offering.

The CD19 Therapeutics Market, 2016-2030' report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of anti-CD19 therapeutics. The recent approval of BLINCYTO®, a CD19 targeting bsAb, and emergence of CAR-T therapies has provided a significant boost to this market that has actively evolved in the past few years.

The pipeline comprises of products across four major classes of drugs, namely, engineered antibodies, bsAbs, ADCs and CAR-T therapies. The major focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table.

Post initial research in CAR-T therapies, many non-industry players have entered into collaborations with industry stakeholders to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include KTE-C19, CTL019, JCAR015 and JCAR017.

One of the key objectives of the study is to review and quantify the opportunities laid by the innovative CD19 targeted programs of both small and big pharma firms.

Amongst other elements, the report elaborates upon the following key areas:

- The current state of the market with respect to key players, developmental stages of pipeline products (both clinical/preclinical) and target indications
- Partnerships that have taken place in the recent past covering research and development collaborations, manufacturing agreements and license agreements specific to technology platforms, product co-development and co-commercialization
- Competitive landscape and inherent threats to growth in the short and long term
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The study provides an estimate of the short-mid term and long term market forecast for the period 2015 - 2030. The research, analysis and insights presented in this report include potential sales of various marketed and late stage (phase II and phase II/III) anti-CD19 products based on our understanding of the likely future development of individual therapeutics. The opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. These included senior representatives at Kite Pharma, MorphoSys and Theravectys.

Example Highlights

- CD19 is an important antigen expressed during B cell development; 80% of all ALL cases, 88% of B cell lymphomas and 100% of B cell leukemias express this antigen.
- During the course of our research, we identified over 50 products in various phases of development. Of these, 70% are in the clinical phase of development (with one molecule in phase II/III trial and six molecules in phase II stage).
- CAR-T therapies (constituting 70% of the development pipeline) are the most common, followed by bsAbs (11%), ADCs (7%) and engineered antibodies (7%).
- The market is highly fragmented with the involvement of several start-ups and many eminent research organizations. Big pharmaceutical players engaged in this space include Amgen, ImmunoGen, MedImmune, Merck and Novartis. Emerging new players/start-ups that are actively investing in this market include Affimed, Bellicum Pharmaceuticals, Juno Therapeutics, Kite Pharma, MorphoSys, Xencor and Zymeworks. The premier research institutes involved in this space include the National Cancer Institute (NCI), MD Anderson Cancer Centre, the University of Pennsylvania, Fred Hutchinson Cancer Research Center (FHCRC) and Memorial Sloan Kettering Cancer Center (MSKCC).
- Hematological malignancies remain the prime focus of drug developers in this space. However, efforts are also being made to use these therapies in the treatment of other indications including certain autoimmune diseases and solid tumors.
- Over the coming decade, we expect at least eight anti-CD19 therapies to be made commercially available in addition to marketed drugs. During this period, we believe the market is likely to expand at an annualized growth rate of 41.0%; the overall opportunity could be much higher and depends on a number of factors such as favourable market environment, regulatory regimes and therapeutic performance of candidates in the late stages of development.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Chimeric Antigen Receptor-T Cell Therapies

6. Engineered Antibodies

7. Bispecific Antibodies

8. Antibody Drug Conjugates (ADCs)

9. Key Therapeutic Areas

10. Market Forecast

11. Conclusion

12. Interview Transcripts

Companies Mentioned - Partial List

- AbDSerotec
- Amphivena
- ADC Therapeutics
- Advaxis
- AFA Försäkring AB
- Affimed
- Agensys
- AgonOx
- AIMM Therapeutics
- Alexion
- Amgen
- arGEN-X
- Astellas Pharma
- AstraZeneca
- Autolus
- Bayer Healthcare
- Baylor College of Medicine
- Beijing Doing Biomedical Co
- Bellicum Pharmaceuticals
- Bio-Rad
- Biotest
- BioWa
- Bluebird Bio
- BoehringerIngelheim
- Cancer Research UK
- Cantargia
- Celgene
- Cellectis
- Cellular Biomedicine Group
- Cephalon
- Center for Cell and Gene Therapy
- Chinese PLA General Hospital
- City of Hope Medical Center
- CSL Limited
- Daiichi Sankyo

For more information visit http://www.researchandmarkets.com/research/s74plx/cd19_therapeutics

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Immune Disorders